ストックスクリーナーアプリを入手
0.825
6.14%
-0.054
プレマーケット:
.83
0.005
+0.61%
前日終値:
$0.879
開ける：
$0.88
24時間の取引高:
98,504
Relative Volume:
0.06
時価総額：
$5.08M
収益：
-
当期純損益:
$-17.06M
株価収益率:
-0.0117
EPS:
-70.7173
ネットキャッシュフロー:
$-14.18M
1週間 パフォーマンス:
+8.70%
1か月 パフォーマンス:
-19.90%
6か月 パフォーマンス:
-86.30%
1年 パフォーマンス:
-98.96%
1日の値動き範囲:
$0.8003
$0.8992
1週間の範囲:
$0.734
$0.8992
52週間の値動き範囲:
$0.7303
$148.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
名前
Cns Pharmaceuticals Inc
セクター
電話
1-800-946-9185
住所
2100 WEST LOOP SOUTH, HOUSTON
CNSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
0.825 | 5.08M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 開始されました | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan
Citadel Advisors LLC Takes Position in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
Jane Street Group LLC Boosts Stake in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Defense World
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit - Barchart.com
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit - citybuzz -
CNSP: Insights on TPI 287's Promise at Brain Tumor Summit | CNSP Stock News - GuruFocus
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | CNSP Stock News - GuruFocus
Brain Cancer Breakthrough: New Drug Achieves 12 Responses in Glioblastoma Patients, FDA Grants Special Status - Stock Titan
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit - Yahoo Finance
CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shift to TPI-287 | CNSP Stock News - GuruFocus
Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved By Stocktwits - Investing.com India
CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan
CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail
CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Canada
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - The Globe and Mail
Jazz Pharma. v. Avadel CNS Pharma: Federal Circuit Applies a Fact-Specific Approach to the Patent Infringement Safe Harbor - JD Supra
CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull
CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan
CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com
CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Stock Titan
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360
Clinical Trials Get a Legal Shield: Federal Circuit Reverses Pharma Patent Injunction - Patently-O
Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNSP stock touches 52-week low at $0.99 amid sharp decline - Investing.com
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Cns Pharmaceuticals Inc (CNSP) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
0.23%
大文字化:
|
ボリューム (24 時間):